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Abstract
Background: Raine syndrome (RS) is a rare autosomal recessive disorder caused by biallelic loss-of-function
mutations of FAM20C. The most common clinical features are microcephaly, exophthalmos, hypoplastic nose and
severe midface hypoplasia, leading to choanal atresia. The radiological findings include generalized osteosclerosis
and brain calcifications. RS is usually lethal during the neonatal period due to severe respiratory distress. However,
there exists a non-lethal RS form, the phenotype of which is extremely heterogeneous. There is paucity of data
about clinical course and life expectancy of these patients.
Results: This is the first description of follow-up features of non-lethal RS patients. Moreover, we present three
unpublished cases.
There are five Asian and two Arab patients. All were born to consanguineous parents. The most common neonatal
comorbidity was respiratory distress secondary to choanal atresia. A variable degree of neurodevelopmental delay
was seen in the majority of our cases and seizures and hearing or vision involvement were also frequent.
Neurological and orthopedic issues were the most frequent complications seen at follow-up in our group.
Persistent hypophosphatemic rickets was the most striking endocrinological manifestation, which was scarcely
responsive to therapy with phosphate salts and alfacalcidol. Life expectancy of our patients goes beyond childhood,
with the oldest of those described being 18 years old at present.
Conclusions: Manifestations of RS in those surviving the neonatal period are being increasingly recognized. Our
study supports previous findings and provides clinical and biochemical observations and data from longer follow
up. Finally, we propose multidisciplinary follow up for patients with non-lethal RS.
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Background
Raine syndrome (RS) (OMIM #259775) is a rare auto-
somal recessive disorder with the estimated prevalence of
< 1 in 1,000,000 [1]. The first description of the phenotype
(congenital sclerosing osteomalacia with cerebral calcifica-
tion) was reported by White et al. in 1985 [2]. But only in
1992 was the eponym “Raine Syndrome” entered into On-
line Mendelian Inheritance In Man (OMIM) as lethal
osteosclerotic bone dysplasia, after the description of a
neonate with osteosclerosis, facial dysmorphism and lethal
cranial anomalies by Raine et al. [3, 4]. More than 15 years
later, the etiology of RS was discovered by Simpson et al
who identified biallelic loss-of-function mutations of
FAM20C (Family with sequence similarity 20, member C)
gene (OMIM*611061), located on chromosome 7p22.3
[5]. FAM20C is a Golgi casein kinase that phosphorylates
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secreted phosphoproteins including fibroblast growth fac-
tor 23 (FGF23) and regulators of hard tissue formation
and bone mineralization [6, 7].
The most classical phenotype was characterized by a
combination of microcephaly, exophthalmos, hypoplastic
nose, low-set ears, gum hypertrophy, cleft palate/uvula,
and severe midface hypoplasia leading to choanal atresia.
The radiological findings include generalized osteo-
sclerosis and brain calcification [8].
Most patients with RS die during the neonatal period
because of severe respiratory distress due to pulmonary
hypoplasia and choanal atresia/stenosis. Despite the ini-
tial assumption that RS was always lethal in the neonatal
period, some authors reported milder phenotypes associ-
ated with survival. The clinical features of non-lethal
forms are extremely heterogeneous. Affected children
can exhibit craniofacial, thoracic and limb abnormalities,
dental and gum alterations, osteosclerosis, hypophospha-
temic rickets and neurological disorders such as seizures
and developmental delay [9–11].
To the best of our knowledge 47 cases of RS are re-
ported so far and of those, 7 children died in the first
two months of life [1, 12–16].
As the clinical features of RS are being increasingly
recognized in surviving children and young people, we
report clinical manifestations to support recent publica-
tions and add follow-up data including management of
non-lethal Raine syndrome.
Results
We present the following seven patients diagnosed with
non-lethal RS: two pairs of affected siblings and 3 single-
tons. Three cases have been published before as original
case reports ([8, 9, 17]) and they are reviewed here for
their prenatal and present characteristics (hereby re-
ferred to as cases IV, VI and VII). Two siblings from
Pakistan are presented as new cases as they were re-
ferred to the Endocrinology Clinic in Italy in 2018 (re-
ferred to as cases I and II); another case from Pakistan
was referred to us by Dr. Adnan Mirza (referred to as
case III).
There were 4 males and 3 females. There are five
Asian and two Arab patients.
The patients’ photos are presented in Fig. 1. Photos of
patients VI and VII are reported elsewhere [9].
Gestational, prenatal and birth characteristics
All the cases reported were born to consanguineous par-
ents. Case VI and VII had a previously deceased sibling
at 7 months of age (no genetic diagnosis was made).
Antenatal investigations revealed one case (case IV) of
intra-uterine growth retardation, one of craniofacial dys-
morphism (initially judged to be compatible with Crou-
zon syndrome) in case V; case II showed bilateral
periventricular hyperechogenicity associated with anom-
alous cranial conformation, though in-utero magnetic
resonance imaging was normal. The mother of case IV
had two previous spontaneous abortions, though no fur-
ther investigation was performed.
Four out of seven patients were born at term, two in-
fants were late preterm at birth, whilst the gestational
age of case I remains unknown (Table 1). Birth weight,
according to the World Health Organization (WHO)
charts [18], was higher than average in four infants, and
lower in two; in one case birth weight was unavailable
(Table 1). It was not possible to retrieve data regarding
length and head circumference at birth of most patients.
Two infants showed normal adaptation to extrauterine
life, while two patients suffered from respiratory distress
and were diagnosed with choanal atresia. One patient
had respiratory distress at birth and choanal stenosis
was documented (Table 1).
Finally, case VII suffered from neonatal cerebral
hypoxic-ischemia following a complicated delivery. The
important antenatal and postnatal complications are
listed in Table 1.
Clinical and radiologic features at diagnosis
Age at the time of clinical and molecular diagnosis
ranged between 4months and 17 years (mean 7.1 years).
An early diagnosis, before one year of age, was made in
three out of seven patients (Table 2). Growth data at
diagnosis was available for only three patients (cases I,
III and V) and showed short stature in all (defined as
height below the third percentile, according to the
WHO charts [18]).
The most common major clinical features observed at
diagnosis were: midface hypoplasia and proptosis (6/7)
and a depressed nasal bridge (6/7) (see Table 2 for other
major clinical features).
The most common minor clinical features at diagnosis
were: gingival hypertrophy, low-set ears, hypertelorism,
dental abnormalities and limb malformations, of which
the most prevalent were clinodactyly of the toes, broad
thumbs and flat feet (Table 2).
Other less commonly reported features were: down-
slanting palpebral fissures and a bulbous nasal tip (cases
II, IV, V, VI), followed by craniofacial disproportion with
narrow bifrontal diameter (cases IV, VI) and a flat fore-
head (case IV), epicanthal folds (case IV), flaring nares
(case IV), prominent philtrum (case IV), pointed chin
(case IV), dark pigmentation of armpits, genitalia and
knuckles (case IV), tented upper lip and frontal bossing
(case V), right convergent strabismus (case II), ante-
verted nostrils (case VI)], high forehead (case I), hypo-
plasic nasal wings (case III), short columella (case I),
inguinal monolateral hernia (case II), maxillary hypopla-
sia (case III) and severe prognathism (case VII).
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Case III also underwent a surgical tracheostomy at day
three of life, was mechanically ventilated for two months
after birth and discharged from hospital on home oxy-
gen therapy and a budesonide inhaler. He underwent
numerous tarsorraphies for severe proptosis.
Tracheostomy was also performed in case V soon after
the birth (3rd day of life).
Regarding neurological involvement, six patients
showed a variable degree of neurodevelopmental delay;
three experienced seizures at the time of diagnosis
(Table 2). Mild sensorineural hearing loss was present in
case VI and VII. Case I presented both severe bilateral
hearing loss and a partial unilateral visual loss due to oc-
clusion of the central retinal artery (Table 2).
Fig. 1 1a-b: Case I at the age of 14 years. 1c: case II at 3 days of life. 1d: case II at 12 months of life. 1e: case III. 1f: case IV at 6 years of age. 1g:
Case V (with permission from reference n° 17)1H: case V (with permission from reference n° 17)
Table 1 Summary of antenatal and postnatal features in non-lethal RS individuals
Pedigree number Case I Case II Case III Case IV Case V Case VI Case VII
Reference Unpublished Unpublished Unpublished [8] [17] [9] [9]
Degree of kinship Siblings Siblings
Gender F M M F M F M
Ethnicity Pakistani Pakistani Pakistani Indian Pakistani Moroccan Moroccan
Other children with
RS in the family
No One No, two previous
spontaneous abortions
No No Noa Noa
Gestational age
(wks)
NA 37 37 36 36 40 39
Weight at birth (g)
/centile (c.le)
NA 2900/30° 3500/90° 2750/
60°
2200/10° 3500/60° 3750/80°
Length at birth
(cm)/ centile (c.le)
NA 50/50° 47/3° NA NA NA NA
Neonatal period NA Choanal stenosis-
respiratory distress
Bilateral choanal atresia-
respiratory distress
Normal Choanal atresia-
respiratory distress -
Hypocalcemic
seizures
Normal Neonatal cerebral
hypoxia-ischemia
c.le percentile; F female, M male NA not available; wks weeks; aOne child deceased at 7 months (the diagnosis was not made)
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The most frequent radiologic findings at diagnosis
were cerebral calcifications and osteosclerosis of long
bones and skull (Table 2).
The principal clinical and radiologic features at diag-
nosis are listed in Table 2.
Table 3 describes the genotype of each patient. All
parents were tested and found to be heterozygous car-
riers of the variants described.
Biochemical features and management at diagnosis
With regard to biochemical findings at the time of diag-
nosis, serum calcium was within the normal range in 4/6
of patients and low in three patients (cases II, III and V).
Hypophosphatemia was found in five out of seven pa-
tients (cases I, II, III, V, VI) (Table 2). Alkaline phos-
phatase (ALP) was found to be either normal (cases III
and VI) or high (cases I, II and V). Serum parathormone
(PTH) level was within normal limits in one patient
(case I) and raised in cases II, V and VI; no data were
available for the other two cases (III, IV, VII). Vitamin D
deficiency was detected in two patients (cases II and V),
while in another case the level was adequate (case I).
One patient (case V) had low tubular phosphate re-
absorption with normal calcium excretion and persist-
ently raised fibroblast growth factor 23 (FGF23),
confirming the diagnosis of FGF23 mediated hypopho-
sphataemia. Unfortunately, the level of FGF23 was not
available in the other patients. Biochemical features at
diagnosis are presented in Table 4.
Three patients required supplementation of calcium
(oral or intravenous), oral phosphate plus oral alfacalci-
diol and cholecalciferol alone or in combination (case I,
II, V).
Follow-up
It was possible to collect data concerning the follow-up of
six out of seven patients (cases I, II, III, V, VI, VII), as it
stands in February 2019. Duration of follow up for cases I,
II, VI, VII was < 4 years and for case V > 5 years. One child
subsequently died at 14months of age (case III).
Table 2 Summary of clinical and radiologic features at diagnosis in non-lethal RS individuals
Pedigree number Case I* Case II* Case III Case IV Case V Case VI° Case VII°
Age at diagnosis 12 yrs 5 mo 4 mo 6 yrs 2 mo 17 yrs 14 yrs
Neurological features
Developmental delay/Seizures +/− +/− +/− +/+ −/+ +/+ +/−
Hearing/vision impairment +/+ −/− −/− – −/− +/− +/−
Major features
Midface hypoplasia/ Microcephaly −/+ +/ + +/+ +/+ +/+ +/− +/+
Depressed nasal bridge/ Hypoplastic nose −/− +/+ +/+ +/+ +/− +/+ +/+
Exophthalmos – + + – + + +
Minor features
Low set ears – – + + + + +
Hypertelorism + – + + + + +
Gingival hypertrophy – – + – – + +
Dental malformations + – + – – + +
Limb malformations + – – + – + +
Radiologic features
Bowing of long bones – – – – + – –
Signs of rickets – – – – + – –
Cerebral calcifications + + – – + + –
Osteosclerosis of skull – + + + + – –
Osteosclerosis of long bones - + + + + – –
Endocrinological features
Short stature + – + – + – –
Hypophosphatemia + + + – + + –
Hypocalcemia – + + – + – –
Rickets – + – – + – –
25 OH Vitamin D deficiency – + – – + – –
mo months; yrs years +: present; −: absent; */° siblings
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Five patients are alive at the time of writing and live
with different comorbidities (cases I, II, V, VI and VII).
Here we present the phenotypic data collected at the last
follow-up visit. Patient ages range between 10months
and 18 years. Follow up frequency and data collected var-
ied between the cases. In particular, the patients were
evaluated regularly until respectively the age of eight (case
V), eighteen years (case VI) and every six months after
diagnosis (case I, II) (case I), at two and eight months of
age in case II and at 5, 8 and 10months in case III.
Endocrinological aspects
Pertaining to growth, severe short stature was observed in
case I. She was tested for growth hormone deficiency and
IGF1 level at the age of 10 years, but was found to be normal.
The study of calcium-phosphate metabolism was rou-
tinely performed during the follow-up according to
clinical judgment in three cases (cases I, II, V) and re-
vealed persistent normo-calcemic hypophosphatemia as-
sociated with high levels of ALP and PTH (Table 5).
Tubular reabsorption of phosphate was low in 2/3
children (case II and case V) and urinary calcium
was normal. Radiographs showed features of rickets
in 2 patients (cases II and V). Given the presence of
hypophosphatemic rickets, cases II and V were pre-
scribed oral phosphate supplementation combined
with oral alfacalcidol. In case II, ALP and PTH sig-
nificantly improved without the development of hy-
percalciuria; a small and not significant reduction in
PTH and ALP level was seen in case V despite in-
creasing doses of both drugs (Table 5). Case I was
treated only with phosphate salts for one year and
then stopped because no improvement in bone
chemistry was seen.
Table 3 Genotype
Pedigree
number and
reference
Case I Case II Case III Case IV [8] Case V [17] Case V I[9] Case VII [9]
Mutation(s) in
FAM20C gene
c.1351G > A
(p.Asp451Asn)
c.1351G > A
(p.Asp451Asn)
c.496G > T
(p.E166X)
c1630C > T
(p.Arg544Trp)
c.1135G > A
(p.G379R)
c.676 T > A
(p.Trp226Arg)
c.676 T > A.
(p.Trp226Arg)
Exon/Intron of
gene
Exon 7 Exon 7 Exon 1 Exon 10 Exon 6 Exon 2 Exon 2
Type of
mutation
Homozygous Homozygous Homozygous Homozygous Homozygous Homozygous Homozygous
Variant
interpretation
Pathogenic
based on
LOVD
database
Pathogenic
based on
LOVD
database
Pathogenic
based on
PVS1 PM2 PP4
Pathogenic
according to
ACMG
guidelines
Pathogenic
according to
ACMG
guidelines
Pathogenic based
on:
SIFT (score0)
Polyphen-2 (score
0.993) Mutation
Taster (score 0.999)
Pathogenic based
on:
SIFT (score0)
Polyphen-2 (score
0.993) Mutation
Taster (score 0.999)
Sequencing
methods
Sanger NGS NGS NGS and Sanger Sanger NGS Sanger
ACMG American College of Medical Genetics and Genomics; LOVD Leiden Open Variation Database; NGS next generation sequencing
Table 4 Biochemical features at diagnosis
Case I Case II Case III Case IV Case V Case VI Case VII
Calcium 10.1 mg/dl
(nv 8.8–10.8)
6.4 mg/dl
(nv 8.8–10.8)
1.78 mmol/l
(nv 2.20–2.79)
10 mg/dl
(nv 8–11 mg/dl)
1.92 mmol/L
(nv 2.20–2.79)
2.45 mmol/l
(nv 2.2–2.6)
NA
Phosphorus 2.7 mg/dl
(nv 4–7)
3.9 mg/dl
(nv 4–7)
1.33 mmol/l
(nv 1.36–2.26)
NA 0.75 mmol/L
(nv 1.36–2.26)
2.2 mg/dl
(nv 2.5–4.5)
NA
ALP 547 U/L
(nv 140–400)
454 U/L
(nv 140–400)
743 IU/L
(nv 187–1197)
NA 5605 IU/L
(nv 187–1197)
70 IU/L
(nv 40–100)
NA
PTH 51.3 pg/ml
(nv 15–65)
129 pg/ml
(nv 15–65)
NA NA 72 pmol/L
(nv 1.1–6.9)
95.3 pg/ml
(nv 15–68)
NA
25OHD 45.6 ng/ml
(nv > 30)
13.8 ng/ml (nv > 30) NA NA < 40 nmol/L
(nv > 50 nmol/L)
NA NA
TRP% NA NA NA NA 72 NA NA
FGF23 NA NA NA NA 157 RU/ml
(nv 0–100)
NA NA
ALP alkaline phosphatase; FGF23 fibroblast growth factor 23; NA not available; NV normal value; PTH parathormone; TRP tubular reabsorption of phosphate; ys
years; 25OHD 25-Hydroxy Vitamin D.
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All patients were currently on vitamin D2 or D3 sup-
plementation because of ongoing deficiency.
We report the isolated finding of low TSH and FT4
level without obvious pituitary pathology (case III).
Neurological development
Microcephaly was confirmed in all investigated cases.
Out of the six analyzed cases, five presented moderate-
to-severe neuro-developmental delay (Table 2). Two pa-
tients (cases V and VII) had reported seizures, one start-
ing at the age of 3 and one at 5 years old. Treatment
with sodium valproate was administered in Case V; dis-
continuation of the drug was unsuccessful due to re-
lapse. Case VII remains without treatment with no
further seizure activity.
Craniostenosis was documented in three cases (cases I,
II and V), two of which (cases II and V) underwent a
ventriculoperitoneal shunt insertion, followed by a surgi-
cal intervention of biparietal decompression and bone
thinning. Cranioplasty surgery is on the agenda for two
patients (cases I and II).
Ear- nose- throat (ENT) aspects
Regarding otorhinolaryngoiatric aspects, a bilateral mir-
ingotomy was performed on case V at the age of four
years due to glue ear. Furthermore, case III he was diag-
nosed with auditory neuropathy spectrum disorder.
Stable hearing loss was reported in case I.
Choanal stenosis was reported to be still present at the
ages of 8 and 12 (case I), while two other siblings were
found to have nasal voice (cases VI and VII).
Moreover, one patient displayed occasional mild laryn-
geal stridor with modestly reduced oxygen-dependency
(case III).
Table 5 Biochemical features during follow-up
Case I Case II Case V
Age 12 ys 6
mo
13 ys 7 mo 14 ys 4 mo 1 y 9 mo 2 mo 7 ys and 3 mo
Pre-
therapy
At the end of the
therapya
At the end of
follow-up
Pre-
therapy
At the end of
follow-up
Pre-
therapy
At the end of
follow-up
Calcium 9.6 mg/
dl
(nv 8.8–
10.8)
9.8 mg/dl
(nv 8.8–10.8)
9.7 mg/dl
(nv 8.8–10.8)
10 mg/dl
(nv 8.8–
10.8)
10.1 mg/dl
(nv 8.8–10.8)
1.92 mmol/
L
(nv 2.20–
2.79)
2.51 mmol/L
(nv 2.20–2.79)
Phosphorus 2.6 mg/
dl
(nv 4–7)
2.2 mg/dl
(nv 4–7)
2.6 mg/dl
(nv 4–7)
2.2 mg/
dl
(nv 4–7)
2.1 mg/dl
(nv 4–7)
0.75 mmol/
L
(nv 1.36–
2.26)
0.73 mmol/L
(nv 1.36–2.26)
ALP 555 U/L
(nv 140–
400)
611 U/L
(nv 140–400)
419 U/L
(nv 140–400)
805 U/L
(nv 140–
400)
487 U/L
(nv 140–400)
5605 IU/L
(nv 187–
1197)
3874 IU/L
(nv 187–1197)
PTH 79 pg/ml
(nv 15–
65)
104 g/ml
(nv 15–65)
74 pg/ml
(nv 15–65)
71 pg/ml
(nv 15–
65)
64 pg/ml
(nv 15–65)
72 pmol/L
(nv 1.1–6.9)
24 pmol/L
(nv 1.1–6.9)
25OHD 39.2 ng/
ml
(nv > 30)
35.2 ng/ml
(nv > 30)
39.2 ng/ml
(nv > 30)
57.9 ng/
ml
(nv > 30)
51.2 ng/ml
(nv > 30)
< 40
nmol/L
(nv > 50
nmol/L)
17 nmol/L
(nv > 50 nmol/L)
TRP% NA 66 NA 76 73 72 NA
FGF23 NA NA NA NA NA 157 RU/ml
(nv 0–100)
NA
CaU/CrU
(< 3 ys:; nv < 0.5
> 3 ys: nv < 0.39)
0.22 0.09 0.12 0.026 0.10 Normal Normal
Therapy with oral phospate
salt
– yes no – yes – yes
Therapy with oral
alfacalcidiol
– no no – yes – yes
Supplementation with oral
cholecalciferol
– yes yes yes yes – yes
ALP alkaline phosphatase; CaU/CrU urine calcium to creatinine ratio; FGF23 fibroblast growth factor 23; Mo months; NA not available; NV normal value; PTH
parathormone; TRP tubular reabsorption of phosphate; 25OHD 25-Hydroxy Vitamin D; ys years; alast measurements before stopping the therapy with
phosphate salts
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Ophthalmological aspects
Case V was diagnosed at six years of age with bilateral
lagophtalmos and exposure keratopathy, requiring bilat-
eral tarsorraphy. Furthermore, bilateral partial optic
nerve atrophy, myopia and astigmatism were detected.
Ophthalmologic follow-up of case I, after initial diag-
nosis of partial unilateral visual loss due to occlusion of
the central retinal artery, remains stable.
Gastrointestinal and feeding
Difficulties in feeding were reported in one patient due
to severe prognathism (case VII). Two patients under-
went gastrostomy placement, case III at the age of four
months and case V at 18 months (with removal at the
age of 4).
Orthopedic aspects
To correct a unilateral lower limb valgus deformity due
to the hypophosphataemic rickets, one patient under-
went an orthopedic surgical intervention of eight-plate
epiphysodesis fixation at the age of seven (case V) with
good effect and improvement in mobility.
During follow-up, one patient was diagnosed with bi-
lateral flat feet and dorsal scoliosis (case I), while an-
other with varism of the inferior limbs (case II).
Miscellaneous
In case V, to correct a mild degree hypospadia and ven-
tral foreskin meatus deficiency, a urological procedure of
meatomy and circumcision was performed at the age of
eight.
Following hemorrhagic complications during surgery,
one patient was tested and diagnosed with a mild type I
Von Willebrand disease (Case V). Severe odontopathy
was documented in two cases (siblings, case I and II).
Discussion
RS is a rare autosomal recessive disorder that tends to
present in the offspring of consanguineous couples. It
was previously considered a lethal condition, but the lit-
erature has demonstrated surviving cases. No clear dis-
tinction between lethal and non-lethal RS has been
made with regards to genetic and phenotypical expres-
sion. However, Hung et al. [16] showed that all the
pathogenic variants responsible for lethal versus non-
lethal Raine phenotype are situated in close proximity to
functional protein regions such as catalytic, dimerization
and glycosylation sites. In contrast, polymorphic changes
reported in healthy homozygotes are found in the helix
furthest away from the catalytic pocket and away from
any of the functional regions.
Evidence is also scarce on life expectancy and clinical
outcome in non-lethal RS. This is the first description of
follow-up features of non-lethal RS patients. Furthermore,
we presented three original previously unpublished cases.
The main epidemiological characteristics of our pa-
tients at diagnosis do not differ from the previous de-
scriptions reported in the literature; all children were
born to consanguinous parents, more frequently of
Asian ethnicity. This report, with the addition of three
new cases, confirmed that most cases were not Cauca-
sian which is likely to be related to the lower prevalence
of consanguinity in this population [1, 19].
The majority of our patients were born at or near
term, consistent with the literature [4, 12, 15, 17]. The
principal neonatal complication was respiratory distress
due to choanal atresia or stenosis. Although the most
striking clinical and radiological features at diagnosis did
not differ from those previously described (midface hy-
poplasia, depressed nasal bridge, generalized osteosclero-
sis and brain calcification), we have reported previously
undescribed clinical features, the most common being a
bulbous nasal tip, not observed in the cases parents and
whose correlation with RS may need further investiga-
tion. Chondrodysplasia punctate, previously reported as
part of the radiological spectrum of the syndrome, was
not observed in our group of patients.
Some degree of neurodevelopmental delay was seen at
diagnosis in the majority of our cases. Seizures occurred
in 43%, and required treatment in 2/3 of the cases. Ab-
normalities in hearing were present in 43%. A variable
degree of hypophosphatemic rickets was detected in the
majority of our group, even though the medical manage-
ment was distinct from case to case. The difference in
management was due to the absence of guidelines spe-
cific for this syndrome.
Overall, we present follow-up data of non-lethal RS in
the single largest cohort of patients and with the longest
follow up duration, the oldest of our patients being 18
years old at present. We, therefore, can support the pre-
vious data that life expectancy for these patients goes be-
yond childhood [19–22]. We found great heterogeneity
in terms of the rate of complications emerging during
follow-up. Orthopedic and neurological issues were the
most frequent in our group: in particular, craniostenosis
requiring surgical intervention and limb anomalies that
were mostly managed conservatively. A moderate-to-
severe neurological delay was present in almost all the
patients. However, systematic homogeneous neuro-
psychiatric evaluations were not performed and we are
unable to define prevalent affected areas. Even though
epilepsy has been described as a component of RS, only
one patient in our group presented with seizures requir-
ing anti-epileptic therapy.
As for endocrinological manifestations, the most strik-
ing feature was persistent hypophosphatemic rickets.
Three patients were treated with the conventional
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therapy used for X-linked hypophosphatemic rickets
(XLHR), given the absence of a specific guideline tai-
lored for RS [23]. However in all cases ALP did not
normalize even using high doses of phosphate salts and
alfacalcidol. The reason for this is unclear but may be re-
lated to the different pathogenesis of the disease com-
pared with XLHR, as well as the underlying
osteosclerosis associated with RS. A possible link be-
tween RS and hypophosphatemic rickets has already
been postulated [17]. FAM20C is known to encode the
human homologue of dentin matrix protein 4 (DMP4)
which is highly expressed in odontoblasts and moder-
ately expressed in bone. Although little is known about
the effects of DMP4, it is likely to play a role in
mineralization, and may be similar to dentin matrix pro-
tein 1, a role for which has already been established in
the inherited forms of hypophosphataemic rickets [24].
This study has some limitations. First of all, the data
were collected retrospectively, and secondly, 50% of the
involved centres are medium or low- health resource
settings, which may have influenced the number of in-
vestigations performed at diagnosis and during follow-
up and the low follow-up rate of patients presented. This
report, however, summarizes the best available know-
ledge of this rare disease.
Conclusion
Our study shows that the clinical course of patients af-
fected by non-lethal RS is extremely variable from case
to case and confirms that survival is possible beyond
childhood. The main complications reported in our
group were neurological and orthopedic. Hypophospha-
temic rickets, scarcely responsive to therapy and short
stature, were the most striking endocrinological manifes-
tations detected in our group.
Based on our experience, we would suggest close monitor-
ing of every patient with a diagnosis of the non-lethal form
of RS with: a) anthropometric evaluation; b) neurological
evaluation to promptly detect neurodevelopment delay and
craniostenosis; c) complete and regular assessment of cal-
cium and phosphate homeostasis; d) orthopedic, otorinolar-
yngeal and ophthalmologic evaluations at least once at
diagnosis and afterwards as clinically required.
Moreover, we aim to continue following the clinical course
of our patients in order to widen our knowledge about the
disease and to update and improve this proposal.
Further studies including a larger number of patients
are needed in order to demonstrate a possible correl-
ation between genetic and phenotypic aspects.
Methods
In September 2018 an initial comprehensive literature
search about RS was performed, and revised/updated in
2019 using Pubmed with no restrictions for language,
type and year of publication. A total of 19 papers related
to paediatric non-lethal RS were found, published be-
tween 1996 and 2019.
Subsequently, all the centers identified through the pa-
pers were contacted and invited by email to take part in
our study. First of all, we approached the corresponding
author. In case of no response, other authors were con-
tacted accordingly. Inclusion criteria were the presence
of new unpublished materials (eg: data, pictures) and/or
at least one follow-up visit of each patient with the non-
lethal form of RS, genetically diagnosed. In addition we
asked all authors if they had other unpublished cases be-
tween the last published paper on this topic and the
study invitation. A total of seven authors agreed to par-
ticipate to our study.
A form including demographical and follow-up data
was sent to all participants. For each patient included in
the study, all the following parameters at diagnosis were
collected: clinical features, imaging, biochemical exami-
nations and treatment, molecular genetics investigations,
hospitalizations and surgery. In order to obtain follow-
up data we collected anthropometry, biochemical, radio-
logical and clinical features, hospitalizations and surgery
from every visit of each patient.
Fasting blood samples (8-h fast) were obtained by
venipuncture. A morning urine sample was collected to
assess urinary creatinine, calcium and phosphate. Gen-
etic test was performed as detailed in Table 3. FGF23
analysis of case V was reported elsewhere [17].
We used descriptive statistics to present demographic,
clinical, and other characteristics of patients.
Data was properly anonymized and sent back to V.
Buzzi Hospital (Milan) by February 2019. This study was
approved by the institutional review board of ASST-
FBF-SACCO. Parents/legal guardians/patients gave con-
sent for publication of clinical photographs.
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